NEW YORK — Nucleic acid manufacturer DNA Script said on Thursday that it has received $1.6 million from the French Defense Innovation Agency to build a prototype qPCR probe manufacturing platform that can be used in the rapid development of biothreat diagnostics.
DNA Script said it will adapt its Syntax benchtop DNA printer for the rapid synthesis of DNA reagents such as Taqman probes that can be used to develop tests for the detection of pathogenic viruses and bacteria. The prototype will then be evaluated by the French Armament General Directorate.
"We are thrilled to collaborate with the French Ministry for Armed Forces on this important initiative to rapidly detect, characterize, and mitigate threats from newly emerging or engineered pathogens," DNA Script CEO Thomas Ybert said in a statement.
In mid-2020, Paris-based DNA Script extended a Series B financing round to $89 million.